Search

Kymera Therapeutics Inc

Fechado

SetorSaúde

117.35 3.11

Visão Geral

Variação de preço das ações

24h

Atual

Mín

111.89

Máximo

117.97

Indicadores-chave

By Trading Economics

Rendimento

8M

-61M

Vendas

31M

65M

EPS

-0.62

Margem de lucro

-94.171

Funcionários

273

EBITDA

6M

-61M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+14.78% upside

Dividendos

By Acuity

Próximos Ganhos

3 de nov. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

777M

9B

Abertura anterior

114.24

Fecho anterior

117.35

Kymera Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

14 de ago. de 2026, 20:06 UTC

Kymera Therapeutics Inc shares are higher today, recovering from an earlier pullback amid a mixed market backdrop following a decline in U.S. retail sales.

12 de ago. de 2026, 20:01 UTC

Kymera Therapeutics Inc shares are trading higher amid increased activity and unusually high market volume, with no specific news identified to explain the movement.

6 de ago. de 2026, 19:56 UTC

Kymera Therapeutics Inc shares are lower today, trading near the lower end of their one-month range amid broader market dynamics and inflationary concerns.

5 de ago. de 2026, 20:02 UTC

Social Media
News

Kymera Therapeutics reported a narrower net loss of $61.21 million for Q2 2026, driven by increased collaboration revenue and a price target raise from Stifel to $132.

4 de ago. de 2026, 20:04 UTC

Correlated Moves

Kymera Therapeutics Inc is rising in Tuesday's session, reflecting bullish sentiment in the biotechnology sector amid a broader market uptrend.

3 de ago. de 2026, 19:46 UTC

News

Kymera Therapeutics Inc shares are lower amid volatility, following Dimensional Fund Advisors LP's 5% stake reduction and broader market trends in biotechnology.

31 de jul. de 2026, 20:06 UTC

Correlated Moves

Kymera shares lower amid SPDR S&P Biotech ETF decline.

30 de jul. de 2026, 19:39 UTC

Kymera Therapeutics Inc shares are higher during Thursday's session, with no specific news identified to explain the price action amid broader market trends.

29 de jul. de 2026, 19:32 UTC

Macro Event

Kymera Therapeutics shares are higher as the Federal Reserve maintains rates at 3.50%–3.75%. Investors monitor inflation trends and their impact on future policy.

28 de jul. de 2026, 17:42 UTC

News
Social Media

Shares lower despite Guggenheim's price target increase to $135.

27 de jul. de 2026, 21:03 UTC

News

Kymera Therapeutics shares are lower in after-market hours following the appointment of Terence Rooney, MD, as Chief Medical Officer, succeeding Jared Gollob, MD.

24 de jul. de 2026, 18:46 UTC

Kymera Therapeutics Inc. shares are roughly flat as trading fluctuates within a narrow range, reflecting routine activity without specific news.

21 de jul. de 2026, 19:16 UTC

Kymera Therapeutics Inc is trading higher, supported by broader market strength and optimism in AI stocks, despite a pullback earlier in the session.

20 de jul. de 2026, 22:16 UTC

Kymera Therapeutics Inc shares are lower in after-market hours. Broader market sentiment is influenced by rising Treasury yields amid interest rate and geopolitical concerns.

Comparação entre Pares

Variação de preço

Kymera Therapeutics Inc Previsão

Preço-alvo

By TipRanks

14.78% parte superior

Previsão para 12 meses

Média 131.33 USD  14.78%

Máximo 155 USD

Mínimo 112 USD

Com base em 18 analistas de Wall Street que oferecem metas de preço de 12 meses para Kymera Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

18 ratings

16

Comprar

2

Manter

0

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
help-icon Live chat